National Bank of Canada FI Sells 3,940 Shares of Illumina, Inc. (NASDAQ:ILMN)

National Bank of Canada FI cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 374,307 shares of the life sciences company’s stock after selling 3,940 shares during the period. National Bank of Canada FI’s holdings in Illumina were worth $51,400,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Lake Street Advisors Group LLC purchased a new stake in Illumina during the first quarter worth $297,000. Bessemer Group Inc. raised its position in shares of Illumina by 81.0% in the 1st quarter. Bessemer Group Inc. now owns 8,587 shares of the life sciences company’s stock worth $1,179,000 after acquiring an additional 3,842 shares in the last quarter. UniSuper Management Pty Ltd lifted its stake in shares of Illumina by 392.7% during the 1st quarter. UniSuper Management Pty Ltd now owns 8,810 shares of the life sciences company’s stock worth $1,210,000 after purchasing an additional 7,022 shares during the last quarter. O Shaughnessy Asset Management LLC boosted its position in Illumina by 91.7% during the first quarter. O Shaughnessy Asset Management LLC now owns 4,199 shares of the life sciences company’s stock valued at $577,000 after purchasing an additional 2,009 shares in the last quarter. Finally, Catalytic Wealth RIA LLC bought a new stake in Illumina during the first quarter valued at about $216,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Performance

NASDAQ ILMN traded up $0.69 on Wednesday, hitting $116.29. 1,314,542 shares of the company’s stock traded hands, compared to its average volume of 2,141,152. The firm’s 50-day moving average price is $109.63 and its two-hundred day moving average price is $124.44. The firm has a market capitalization of $18.52 billion, a PE ratio of -14.27 and a beta of 1.15. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $195.64.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the previous year, the firm posted $0.08 earnings per share. The firm’s quarterly revenue was down 1.0% on a year-over-year basis. As a group, analysts expect that Illumina, Inc. will post 1.38 EPS for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of recent research reports. Scotiabank reduced their target price on shares of Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a report on Monday, May 6th. Barclays increased their target price on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. Robert W. Baird lifted their price target on shares of Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. TD Cowen lowered their price objective on Illumina from $140.00 to $122.00 and set a “hold” rating for the company in a research report on Thursday, June 6th. Finally, StockNews.com began coverage on Illumina in a research report on Sunday, June 30th. They set a “buy” rating on the stock. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average target price of $158.57.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.